Three Healthcare Stocks with Durable Moats for Patient Capital in 2026

The healthcare sector presents a classic value investing paradox. On one hand, it is a defensive bastion, with essential services that compound through economic cycles. On the other, it is navigating a period of profound financial strain. For patient capital, the challenge is to separate the noise of near-term pressure from the enduring strength of durable competitive advantages.

The financial pressure is quantifiable. Industry profitability, measured as EBITDA as a percentage of national health expenditures, has been on a steady decline, falling from 11.2% in 2019 to 8.9% in 2024. The trajectory suggests more headwinds ahead, with the metric expected to dip to 8.7% in 2027. This squeeze is being felt across the system, from payers facing enrollment shifts to providers grappling with reimbursement and uncompensated care. The sentiment among those running these systems reflects this unease. While their global peers remain largely optimistic, a notable shift is occurring in the United States. 20% of US health system leaders expressed a negative industry outlook for 2026, a sharp increase from the 3% uncertainty reported a year ago.

From a value perspective, this environment is not a reason to flee, but a filter. It highlights the critical importance of a wide moat. In a sector where margins are under siege, only companies with scale, regulatory advantages, or essential services can protect their economic engine and fund the reinvestment needed to compound over decades. The defensive nature of healthcare spending provides a long-term tailwind, as people do not typically delay necessary care. Yet, the current financial strain means that not all operators are equally positioned to weather the storm or emerge stronger.

The key for the disciplined investor is to identify those operators whose moats are wide enough to insulate them from the sector's average pressures. This is where the analysis shifts from the broad industry to the individual company's competitive position. The goal is to find businesses that can maintain their intrinsic value and continue to generate cash, regardless of the temporary turbulence in the sector's profit pool.

HCA Healthcare: A Defensive Compounder with a Catalyst

HCA Healthcare stands out as a defensive compounder in a pressured sector. Its stock is up 7% so far in 2026, a notable outperformance against the broader market. This resilience is built on a foundation of scale and essential service provision. The company operates a vast, diversified network of facilities across the U.S. and the U.K., creating a wide moat. This scale provides a steady stream of cash flow, allowing HCA to fund reinvestment and weather industry volatility.

Financially, the company demonstrated strength in its latest quarter, with revenue rising 6.7% to $19.5 billion and adjusted earnings per share surging 28.8% to $8.01. Yet its forward guidance presents a more modest picture, with fiscal 2026 revenue expected in a range that implies about 3.5% growth at the midpoint. This cautious outlook is directly linked to a key headwind: regulatory uncertainty. The expiration of enhanced premium tax credits, which had been boosting patient demand and admissions, has created a near-term challenge.

This regulatory overhang is the primary catalyst for the stock. Its resolution-whether through legislative extension or a clearer policy path-could unlock significant value. It would remove a major source of volatility and support HCA's long-term growth strategy, which is anchored by demographic tailwinds from an aging population. The company's consistent market share gains and investments in areas like AI-driven care improvements further fortify its competitive position.

For the patient investor, HCA represents a bet on a durable business navigating a temporary overhang. Its financial resilience and vast network provide a margin of safety. The stock's outperformance in early 2026 suggests the market is already pricing in some of this strength. The real opportunity lies in the potential for the regulatory cloud to clear, which could re-rate the stock and support its ability to compound cash flow for decades.

AbbVie: A Cash Machine with a Pipeline Catalyst

For the patient investor, AbbVie represents the ideal blend of a cash-generating fortress and a pipeline poised for a breakthrough. The company is cited as a stock with plenty of long-term upside, a view anchored in its ability to sustain high returns on capital. Its defensive profile is clear: a diversified portfolio of blockbuster drugs, a history of consistent dividend increases, and a track record of outperforming in downturns. This stability is the foundation for patient capital.

The Horizon Therapeutics acquisition has been critical in fortifying that foundation. It provided a crucial revenue diversification away from Humira, which faces a patent cliff. More importantly, it injected a high-growth asset into the portfolio. This strategic move has helped AbbVie navigate the transition, allowing it to project combined $31 billion in revenue from Skyrizi and Rinvoq in 2027. The financial engine remains robust, with analysts expecting the company to maintain high-single-digit compound annual revenue growth through 2029.

The specific catalyst for future earnings growth, however, is the potential approval and launch of its MariTide GLP-1 obesity drug. This is the next major step in the company's evolution. The GLP-1 market is a massive, expanding opportunity, with experts forecasting it to grow to $254 billion by 2034. A successful entry would significantly expand AbbVie's market, adding a new pillar of growth to complement its established immunology franchise. It would also provide a direct counter to the headwinds from Humira's patent expiration.

The bottom line is that AbbVie is a compounder in transition. Its current cash flow provides a wide moat and a margin of safety. The MariTide catalyst, if realized, could re-rate the stock and extend its growth runway for another decade. For patient capital, the investment is a bet on a durable business successfully launching its next blockbuster.

Catalysts and Risks: What to Watch for Patient Capital

For patient capital, the path to compounding is rarely a straight line. It is paved with specific milestones and tested by persistent headwinds. The catalysts for HCA Healthcare and AbbVie are clear, but they unfold against a backdrop of sector-wide financial pressure that remains the primary risk for both.

For HCA, the immediate catalyst is the resolution of a regulatory overhang. The expiration of enhanced Affordable Care Act subsidies in 2026 has created a near-term challenge for patient demand and admissions. The stock's outperformance suggests the market is already looking past this, but the full catalyst is the adoption of new care models and pricing strategies that can stabilize the financial engine. The company's vast network and scale provide a margin of safety, but its ability to navigate this transition will test its financial resilience and determine if it can maintain its growth trajectory.

AbbVie's catalyst is more product-driven. The potential approval and launch of its MariTide GLP-1 obesity drug represents a major growth catalyst. This is the next step in the company's evolution, a direct counter to the headwinds from Humira's patent expiration. Success here would significantly expand its market and add a new pillar of growth. The key watchpoints are clinical data readouts and regulatory milestones, which will define the timeline and commercial potential of this next blockbuster.

Yet, the primary risk for both companies is the persistent sector-wide pressure on margins and reimbursement. The industry's EBITDA as a percentage of national health expenditures is expected to dip to 8.7% in 2027, a sign of continued financial strain. For HCA, this means providers could face an increase in uncompensated care and loss of reimbursement. For AbbVie, it means ongoing pressure on drug pricing and payer negotiations. This environment compresses earnings if not managed with discipline. The wide moats of these companies-HCA's scale and AbbVie's diversified portfolio-are their best defenses, but they must be actively managed to protect intrinsic value.

The bottom line is that patient capital must look past quarterly noise to these longer-term catalysts and risks. HCA's story hinges on regulatory clarity and operational adaptation. AbbVie's hinges on pipeline execution. Both must succeed in an industry where the average profit pool is under siege. The disciplined investor's job is to assess whether these specific companies have the competitive advantages and management fortitude to navigate the turbulence and compound for decades.